A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
S-1 plus weekly split-dose cisplatin demonstrated promising results in previous phase
I and II studies for advanced gastric cancer (AGC) patients.